Back to CVE records
Medium 6.8Published May 27, 2026

CVE-2026-9704Keycloak: keycloak: privilege escalation due to oversized subject_token jwt

Updated under an hour ago ()

This data is behind schedule: last updated Oct 26, 2026, 6:40 AM ET. We are working on it.Behind: CVE records (cvelistV5).

Does this affect you?

It affects Red Hat build of Keycloak 26.4 and 1 other product. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

A flaw was found in Keycloak. An authenticated user with low privileges can exploit this vulnerability by sending an oversized subject_token JSON Web Token (JWT) to the TokenEndpoint. When the token exceeds a 4000-character limit, it is silently dropped, causing the system to fall back to client credentials. This allows the user to gain the permissions of the client's service account, leading to privilege escalation.

CVSS
6.8 MEDIUM (v3.1, CNA)CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:H/I:H/A:N
Weakness (CWE)
CWE-1284
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
redhat
NVD analysis
Modified
Record last updated
Jun 26, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
from 26.4.13-1 not affected
CNA record
redhat build_of_keycloak
redhat:build_of_keycloak
all versions
NVD

References

  • vendor-advisory, x-refsource-redhat
  • vendor-advisory, x-refsource-redhat
  • vendor-advisory, x-refsource-redhat
  • vendor-advisory, x-refsource-redhat
  • vdb-entry, x-refsource-redhat, mitigation, vendor-advisory
  • issue-tracking, x-refsource-redhat, vendor-advisory

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.